ACE-gen polymorphism and cardiovascular diseases

Klinik und Poliklinik für Innere Medizin II, Universität Regensburg.
Herz (Impact Factor: 0.69). 03/2000; 25(1):1-6. DOI: 10.1007/BF03044118
Source: PubMed


The angiotensin converting enzyme (ACE) is an integral part of enzymatic cascades leading to generation of angiotensin II as well as degradation of bradykinin. For this reason, it represents an important part for the metabolism of 2 vasoactive peptides. Early in this decade, convincing experimental evidence demonstrated the induction of this enzyme in several pathophysiological conditions including myocardial infarction and left ventricular hypertrophy. In parallel, a deletion/insertion (D/I) polymorphism of the human ACE gene was discovered that was related to 14 to 50% of the interindividual variance of serum ACE activity. More recently, this polymorphism was implicated in the pathogenesis of a variety of cardiovascular disorders including myocardial infarction, left ventricular hypertrophy, hypertension as well as nephropathy.

3 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Angiotensin-converting enzyme (ACE) is primarily localized (>90%) in various tissues and organs, most notably on the endothelium but also within parenchyma and inflammatory cells. Tissue ACE is now recognized as a key factor in cardiovascular and renal diseases. Endothelial dysfunction, in response to a number of risk factors or injury such as hypertension, diabetes mellitus, hypercholesteremia, and cigarette smoking, disrupts the balance of vasodilation and vasoconstriction, vascular smooth muscle cell growth, the inflammatory and oxidative state of the vessel wall, and is associated with activation of tissue ACE. Pathologic activation of local ACE can have deleterious effects on the heart, vasculature, and the kidneys. The imbalance resulting from increased local formation of angiotensin II and increased bradykinin degradation favors cardiovascular disease. Indeed, ACE inhibitors effectively reduce high blood pressure and exert cardio- and renoprotective actions. Recent evidence suggests that a principal target of ACE inhibitor action is at the tissue sites. Pharmacokinetic properties of various ACE inhibitors indicate that there are differences in their binding characteristics for tissue ACE. Clinical studies comparing the effects of antihypertensives (especially ACE inhibitors) on endothelial function suggest differences. More comparative experimental and clinical studies should address the significance of these drug differences and their impact on clinical events.
    The American Journal of Cardiology 11/2001; 88(9A):1L-20L. DOI:10.1016/S0002-9149(01)01878-1 · 3.28 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Gegenwärtige Fortschritte in den pharmakologischen Wissenschaften erlauben einen ersten Ausblick auf eine individuelle, genotyp-basierende Arzneimitteltherapie, durch die sich die Effektivität der Medikamentenbenutzung weiter verbessern ließe. Die genotypische Erfassung von genetischen Polymorphismen, die bei Medikamentenreaktionen beteiligt sind, verspricht die Arzneimitteltherapie grundlegend zu optimieren, wenn damit Patienten identifiziert werden, für die ein Medikament entweder nutzbringend und sicher angewandt oder aber aufgrund zu erwartender Nebenwirkungen nicht eingesetzt werden sollte. Die neuen pharmakogenomischen Behandlungsstrategien werfen komplexe ethische Fragestellungen auf, da durch ein genetisches Screening für Arzneimittelzwecke asymptomatische Patienten mit erhöhtem Risiko für eine insgesamt schlechtere Prognose identifiziert werden könnten. Die Pharmakogenomik beeinflusst damit das Beziehungsverhältnis zwischen behandelnden Arzt und Patienten, das traditionell auf Diskretion, Vertraulichkeit und dem unbedingten Vorsatz, heilen und keinesfalls schaden zu wollen, beruht. Der vorliegende Aufsatz diskutiert einige ethische Aspekte im Bedeutungswandel der Arzt-Patienten-Beziehung, der durch diesen neuartigen pharmakogenomischen Behandlungsansatz ausgelöst wird. Definition of the problem: Recent progress in the pharmacological sciences provides a first glimpse of the development of an individual, genotype-based drug therapy in order to improve the efficiency of drug utilization. Genotyping of genetic polymorphisms in genes involved in drug response promises to optimize drug therapy fundamentally by identifying patients for whom a pharmaceutical agent may be effective and safe or contraindicated because of expected adverse drug reactions. Arguments: The new pharmacogenomic treatment strategies raise complex bioethical issues, because genetic screening for drug therapy may identify asymptomatic patients who are at risk for a particular adverse outcome. Thus, pharmacogenomics will affect the relationship between the treating physician and the patient which is traditionally based on privacy, confidentiality, beneficience and non-maleficience. Conclusion: In the article presented some ethical aspects of these new pharmacogenomic approaches concerning the physician-patient relationship are discussed.
    Ethik in der Medizin 02/2002; 14(1):3-10. DOI:10.1007/s00481-002-0157-6 · 0.33 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this study was to investigate the role of angiotensin-converting enzyme gene polymorphism in patients with coronary artery disease in north India. One hundred forty-six patients with angiographically proven atherosclerotic coronary artery disease, and 146 age- and sex-matched control subjects (treadmill-negative) were included in the study. Genomic DNA was extracted and analyzed for angiotensin-converting enzyme insertion/deletion polymorphism. Two independent investigators scored the genotypes. When we compared the genotypes of patients with coronary artery disease with those of normal controls, it was seen that all three genotypes, i.e. DD, ID and II, were not statistically different among patients and controls. Further, we categorized the patient and control groups into 2 subgroups, i.e. below and above 50 years of age. Interestingly, it was observed that the DD genotype was significantly higher in patients in the higher age group (i.e. above 50 years of age). However, this needs further validation by studying patients with coronary artery disease from other parts of India.
    Indian Heart Journal 01/2004; 56(1):44-6. · 0.17 Impact Factor
Show more

Similar Publications